Key Record Dates
| ClinicalTrials.gov Identifier: | NCT05325866 |
|---|---|
| Brief Title: | A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301) |
| First Submitted : | April 6, 2022 |
| First Submitted that Met QC Criteria : | April 6, 2022 |
| First Posted : | April 13, 2022 |
| Last Update Submitted that Met QC Criteria : | May 8, 2024 |
| Last Update Posted : | May 9, 2024 |